[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551378":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":42,"locations":52,"responsibleParty":81,"collaborators":83,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":32,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":55,"whyStopped":32,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin hydrochloride","EXPERIMENTAL","1000 mg\u002Fday Metformin hydrochloride extended-release tablets",[13],"Drug: Metformin Hydrochloride tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","1000 mg\u002Fday placebo",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Metformin Hydrochloride tablet","Extended release oral tablets, 1000 mg\u002Fday, single dose",[9],[27],"Metformin",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Oral tablets, 1000 mg\u002Fday, single dose",[15],null,[34,37,39],{"name":35,"affiliation":5,"role":36},"Guoguang Zhao, professor","STUDY_CHAIR",{"name":35,"affiliation":5,"role":38},"PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":5,"role":41},"Jing Li, professor","STUDY_DIRECTOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":32,"email":47},"Lingling Geng","CONTACT","18510932169","gengll@xwhosp.org",{"name":49,"role":45,"phone":50,"phoneExt":32,"email":51},"Gele Qu","13601310067","qugeyue@xwhosp.org",[53],{"facility":54,"status":55,"city":56,"state":32,"zip":32,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Xuanwu Hospital Capital Medical University","RECRUITING","Beijing","China","CN",{"type":60,"coordinates":61},"Point",[62,63],116.39723,39.9075,{"lat":63,"lon":62},[66,70,74,75,78,79],{"name":67,"role":45,"phone":68,"phoneExt":32,"email":69},"Ming Yi","13269087337","yiming1005@163.com",{"name":71,"role":45,"phone":72,"phoneExt":32,"email":73},"Liyun Zhao","17801137417","zhaoliyun1992@163.com",{"name":35,"role":38,"phone":32,"phoneExt":32,"email":32},{"name":76,"role":77,"phone":32,"phoneExt":32,"email":32},"Guanghui Liu, professor","SUB_INVESTIGATOR",{"name":40,"role":77,"phone":32,"phoneExt":32,"email":32},{"name":80,"role":77,"phone":32,"phoneExt":32,"email":32},"Weiqi Zhang, professor",{"type":82,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[84,87,89],{"name":85,"class":86},"Institute of Zoology, Chinese Academy of Sciences","OTHER_GOV",{"name":88,"class":86},"Beijing Institute of Genomics, Chinese Academy of Sciences",{"name":90,"class":91},"Merck Serono Co., Ltd., China","INDUSTRY","100551378","phase-2-pilot-study-on-evaluating-the-geroprotective-effect-of-metformin-100551378",false,"NCT06459310","Pilot Study on Evaluating the Geroprotective Effect of Metformin","A Phase II Exploratory Clinical Study Investigating the Geroprotective Effect of Metformin in Middle-aged and Elderly People","AGE-M","Inclusion Criteria：\n\n1. Male\n2. Age 55-65; 18-28;\n3. Able to understand and execute instructions;\n4. After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol;\n5. Be able to participate in regular follow-up visits.\n\nExclusion Criteria\n\n1. Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine \\>1.5 mg\u002Fdl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases;\n2. BMI\\\u003C18.5 or BMI\\>30;\n3. Persistent alcohol or drug abuse;\n4. Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin);\n5. Hypersensitivity to metformin or any component of the preparation;\n6. Have taken metformin, low-dose aspirin, acarbose, vitamin C in the recent (3 months);\n7. Unable to provide informed consent;\n8. Other circumstances in which the researcher believes that the physical factors of the participants may adversely affect the research process or results.",true,"MALE","18 Years","65 Years",{"count":105,"type":106},130,"ESTIMATED","INTERVENTIONAL",[109],"PHASE2","The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.",[27,112],"Aging",[114,115,116,117,118,119,120],"aging intervention","metformin","aging biomarker","multi-omics","middle-aged and elderly people","molecular clocks","biological age","2025-03-18",{"date":123,"type":124},"2025-03-21","ACTUAL",{"date":126,"type":124},"2024-06-30",{"date":128,"type":106},"2028-07-31",{"name":5,"class":6},1]